Fast-food chain Wendy’s (NASDAQ:WEN) reported revenue ahead of Wall Street’s expectations in Q4 CY2024, with sales up 6.2% year on year to $574.3 million. Its non-GAAP profit of $0.25 per share was in line with analysts’ consensus estimates.
Footwear company Crocs (NASDAQ:CROX) reported Q4 CY2024 results topping the market’s revenue expectations, with sales up 3.1% year on year to $989.8 million. On the other hand, next quarter’s revenue guidance of $905.8 million was less impressive, coming in 2.3% below analysts’ estimates. Its non-GAAP profit of $2.52 per share was 11.3% above analysts’ consensus estimates.
Energy and industrial distributor DistributionNOW (NYSE:DNOW) announced better-than-expected revenue in Q4 CY2024, with sales up 2.9% year on year to $571 million. Its non-GAAP profit of $0.25 per share was 92.3% above analysts’ consensus estimates.
Beauty supply retailer Sally Beauty (NYSE:SBH) met Wall Street’s revenue expectations in Q4 CY2024, but sales were flat year on year at $937.9 million. On the other hand, next quarter’s revenue guidance of $899.3 million was less impressive, coming in 2.3% below analysts’ estimates. Its non-GAAP profit of $0.43 per share was in line with analysts’ consensus estimates.
Bitcoin continues to trade in a range that it has set since mid-November.
Beer company Molson Coors (NYSE:TAP) reported Q4 CY2024 results beating Wall Street’s revenue expectations, but sales fell by 2% year on year to $2.74 billion. Its non-GAAP profit of $1.30 per share was 15.3% above analysts’ consensus estimates.
Healthcare technology company GE HealthCare Technologies (NASDAQ:GEHC) met Wall Street’s revenue expectations in Q4 CY2024, with sales up 2.2% year on year to $5.32 billion. Its non-GAAP profit of $1.45 per share was 14.8% above analysts’ consensus estimates.
Musk said the action of “deleting” entire agencies is necessary to prevent future administrations from rehiring for what he believes are unnecessary roles.
Agricultural and construction machinery company Deere (NYSE:DE) missed Wall Street’s revenue expectations in Q4 CY2024, with sales falling 18.9% year on year to $8.51 billion. Its GAAP profit of $3.19 per share was 1.8% below analysts’ consensus estimates.
Healthcare products company West Pharmaceutical Services (NYSE:WST) reported Q4 CY2024 results topping the market’s revenue expectations, with sales up 2.3% year on year to $748.8 million. On the other hand, the company’s full-year revenue guidance of $2.89 billion at the midpoint came in 5% below analysts’ estimates. Its non-GAAP profit of $1.82 per share was 5.3% above analysts’ consensus estimates.
